Trial Profile
Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition With Pembrolizumab in Combination With PARP Inhibition With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancers
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 15 Dec 2023 Planned End Date changed from 8 Nov 2024 to 8 Aug 2026.
- 15 Dec 2023 Planned primary completion date changed from 8 Nov 2023 to 8 Aug 2026.
- 03 Jun 2023 Status changed from active, no longer recruiting to recruiting.